At the “Safeguarding and Improving People's Livelihood in High-Quality Development” situation policy series held recently, Yin Hejun, Party Secretary and Minister of Science and Technology, said that artificial intelligence, robots, and innovative drugs known as the “three new and new” are developing rapidly and are expected to form a new pillar industry. According to data from a platform, from July 13 to 19, the weekly call volume of China's big model reached 36.11 trillion terms, an increase of 30.93% over the previous month. It achieved growth for eight consecutive weeks, ranking first in the world for 12 consecutive weeks. In the first half of this year, China's robot exports reached 6.29 billion yuan. Products were sold to 141 countries and regions around the world, and the export value of surgical robots increased 3.3 times. In the first half of the year, China's innovative drug authorized transactions were about 110 billion US dollars, and Chinese pharmaceutical companies occupied 8 seats in the top ten global pharmaceutical transactions.

At the “Safeguarding and Improving People's Livelihood in High-Quality Development” situation policy series held recently, Yin Hejun, Party Secretary and Minister of Science and Technology, said that artificial intelligence, robots, and innovative drugs known as the “three new and new” are developing rapidly and are expected to form a new pillar industry. According to data from a platform, from July 13 to 19, the weekly call volume of China's big model reached 36.11 trillion terms, an increase of 30.93% over the previous month. It achieved growth for eight consecutive weeks, ranking first in the world for 12 consecutive weeks. In the first half of this year, China's robot exports reached 6.29 billion yuan. Products were sold to 141 countries and regions around the world, and the export value of surgical robots increased 3.3 times. In the first half of the year, China's innovative drug authorized transactions were about 110 billion US dollars, and Chinese pharmaceutical companies occupied 8 seats in the top ten global pharmaceutical transactions.